Pharmacokinetic interaction in beagle dogs of antiplatelet drugs: acetylsalicylic acid, dipyridamole and calcium dobesilate.
In clinical practice, the co-administration of antiplatelet drugs, such as acetylsalicylic acid (ASA) and dipyridamole (DP) and calcium dobesilate, is often recommended in order to obtain secondary prophylaxis against certain ischaemic diseases. Therefore the possible pharmacokinetic interactions between these three drugs were studied after a single-dose in beagle dogs. The plasma concentrations of ASA, DP and CaDb were measured by HPLC. It was found that the DP and CaDb kinetics were unaffected by concurrent intake of ASA, DP or CaDb. However, concurrent DP or CaDb improved the bioavailability of ASA, particularly the increased Cmax and (AUC).
Laboratory for Experimental Surgery and Surgical Research, School of Medicine, University of Athens, Greece.
C T
CT
Plessas
S
S
Souras
P E
PE
Karayannacos
S T
ST
Plessas
I
I
Dontas
D
D
Kotsarelis
G
G
Asimakopoulos
J
J
Gogas
D000284:Administration, Oral; D000818:Animals; D001241:Aspirin / Q000493:pharmacokinetics*; D001557:Benzenesulfonates / Q000493:pharmacokinetics*; D001682:Biological Availability; D002123:Calcium Dobesilate / Q000493:pharmacokinetics*; D004176:Dipyridamole / Q000493:pharmacokinetics*; D004285:Dogs; D004347:Drug Interactions; D005260:Female; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000493:pharmacokinetics*
D001557:Benzenesulfonates; D010975:Platelet Aggregation Inhibitors; D002123:Calcium Dobesilate; D004176:Dipyridamole; D001241:Aspirin